Current and future pharmacotherapy options for non-cystic fibrosis bronchiectasis. (3rd July 2018)

• Record Type: Journal Article
• Authors: Athanazio, Rodrigo; da Costa, Joao Cordeiro; de la Rosa Carrillo, David; Martínez-García, Miguel Ángel
• Is Part Of: Expert review of respiratory medicine. Volume 12:Number 7(2018)
• Page Start: 569
• Page End: 584
• Publication Date: 2018-07-03
• Subjects: Bronchiectasis -- bronchial infection -- inhaled antibiotics -- bronchodilators -- inhaled steroids -- mucus clearance techniques -- mucoactive agents -- macrolides -- mucolytics -- hypertonic agents; Respiratory organs -- Diseases -- Periodicals; Respiratory organs -- Diseases -- Treatment -- Periodicals; 616.2005
• DOI: 10.1080/17476348.2018.1481392
• Languages: English
• ISSNs: 1747-6348

Abstract

ABSTRACT: Introduction : In recent years, there has been an increasing number of clinical trials investigating the effect of pharmacological treatments on patients with bronchiectasis. Areas covered : This review provides an overview of current drugs used in bronchiectasis patients as well as those that could make a future contribution to the management of this disease. Expert commentary : Bronchiectasis is a very heterogeneous disease, so it can be studied from a phenotypic standpoint and its pathophysiological mechanisms (endotypes) can be defined. This provides an interesting field of research as it enables the identification of patients suitable for inclusion in specific clinical trials on new drugs.